Bristol-Myers Squibb Company Earnings
The next earnings date for Bristol-Myers Squibb Company is July 30, 2026.
They are scheduled to announce earnings before the market opens that day.
Analyst Estimates of Bristol-Myers Squibb Company Earnings
| 07/30/2026 | $1.62 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Bristol-Myers Squibb Company Earnings: Historical
| 04/30/2026 | Before Market | $1.58 | 11.27% |
| 02/05/2026 | Before Market | $1.26 | 5.00% |
| 10/30/2025 | Before Market | $1.63 | 7.24% |
| 07/31/2025 | Before Market | $1.46 | 32.73% |
| 04/24/2025 | Before Market | $1.80 | 20.00% |
| 02/06/2025 | Before Market | $1.67 | 13.61% |
| 10/31/2024 | Before Market | $1.80 | 20.00% |
| 07/26/2024 | Before Market | $2.07 | 26.99% |
| 04/25/2024 | Before Market | $-4.40 | -6.28% |
| 02/02/2024 | Before Market | $1.59 | 11.19% |
More About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
“Bristol-Myers Squibb Company Earnings” Can Refer to the Bristol-Myers Squibb Company Earnings Date
Some people say “Bristol-Myers Squibb Company earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Bristol-Myers Squibb Company position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Bristol-Myers Squibb Company Stock on the Earnings Date
If you own Bristol-Myers Squibb Company stock (BMY) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Bristol-Myers Squibb Company might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Bristol-Myers Squibb Company shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Bristol-Myers Squibb Company Options on the Earnings Date
If you own Bristol-Myers Squibb Company options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Bristol-Myers Squibb Company options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Bristol-Myers Squibb Company options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Bristol-Myers Squibb Company. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Bristol-Myers Squibb Company options often go down. This is sometimes referred to as volatility crush.
Learning More Bristol-Myers Squibb Company Earnings
You can contact us any time if you would like to ask questions about Bristol-Myers Squibb Company earnings or anything else related to the stock market.